A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)

Status: Open to Accrual

Learn more:

• clinicaltrials.gov: #NCT04690855

Study Contact: studies@hoosiercancer.org; (317) 921-2050.